Principal Investigator

Steven J
Awardee Organization

Massachusetts General Hospital
United States

Fiscal Year
Activity Code
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery

This administrative supplement seeks support for administration of the Uterine Lavage Study by the principal investigator and a research coordinator. Since the study has become a multi-year study due to COVID and other reasons, and administrative support was only available for the first year, support is needed to maintain administration of the study in a cohesive and organized fashion. The Uterine Lavage Study (ULS) aims to elucidate the relative contributions to detection of ovarian cancer from tumor DNA in uterine lavage (UL) and in Pap smears, and protein biomarkers from blood, uterine lavage, and Pap smear fluid, using newly available detection and sample collection technologies. Six sites will enroll patients into this study into two cohorts. In the first cohort, the study will enroll 200 patients scheduled for surgery for suspected ovarian cancer. Enrolling patients prior to surgical diagnosis ensures the study will be PRoBE compliant. Up to two blood draws will be obtained preoperatively or up to 31 days prior to surgery, and a uterine lavage and Pap smear will be obtained immediately prior to surgery. The expectation is that ~50 of these patients will have pathologically confirmed ovarian cancer. In a second cohort, 50 patients with an inherited BRCA1 or BRCA2 deleterious mutation without suspected ovarian cancers who are scheduled for risk-reducing salpingooophorectomy (RRSO) will be enrolled. Based on published reports, it is expected that that ~5 patients will have microscopic or low volume ovarian cancer identified on SEE-FIM pathologic examination. In each cohort, the patients with a pathologic invasive epithelial ovarian cancer diagnosis will be defined as Cases and patients without any ovarian cancer, primary peritoneal cancer (PPC), or other cancer identified due to the surgery, will be defined as Controls. Other cancer groups are: (i) PPC, (ii) noninvasive serous tubal intraepithelial carcinoma (STIC) lesions, (iii) non-epithelial ovarian cancers, and (iv) non-ovarian cancers. Analytic sites will determine TP53 mutation status and 25-gene panel mutation status, targeted methylation, global methylation, and protein abundances in the uterine lavage, Pap smear biospecimens, and in blood for cases and controls. Statistical analyses will identify biomarkers which distinguish cases from controls with a high specificity, and determine the complementarity of biomarkers from each biospecimen. Such analyses will identify a classifier based on a panel of biomarkers that is likely to serve as high probability candidates for the early detection of ovarian cancer.


  • Skates SJ. A statistical challenge: developing tests for biomarker utility specific to the intended use. Journal of the National Cancer Institute. 2014 Apr;106(4):dju076. Epub 2014 Mar 28. PMID: 24681600
  • Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, Goode EL, Menon U, Jacobs IJ, Gayther SA, Pharoah PD. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Sep 10;33(26):2901-7. Epub 2015 Aug 10. PMID: 26261251
  • Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. Journal of proteome research. 2013 Dec 6;12(12):5383-94. Epub 2013 Oct 28. PMID: 24063748
  • Taylor MS, Wu C, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cajuso T, Cheng WC, Heaps JD, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Chait BT, Goggins MG, Bhan I, Franses JW, Yang X, Taplin ME, Wang X, Christiani DC, Johnson BE, Meyerson M, Uppaluri R, Egloff AM, Denault EN, Spring LM, Wang TL, Shih IM, Fairman JE, Jung E, Arora KS, Yilmaz OH, Cohen S, Sharova T, Chi G, Norden BL, Song Y, Nieman LT, Pappas L, Parikh AR, Strickland MR, Corcoran RB, Mustelin T, Eng G, Yilmaz ÖH, Matulonis UA, Chan AT, Skates SJ, Rueda BR, Drapkin R, Klempner SJ, Deshpande V, Ting DT, Rout MP, LaCava J, Walt DR, Burns KH. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer discovery. 2023 Dec 12;13(12):2532-2547. PMID: 37698949
  • Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Oct 10;32(29):3275-83. Epub 2014 Sep 8. PMID: 25199754
  • Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, Gentry-Maharaj A, Kalsi JK, Singh N, Amso NN, Cruickshank D, Dobbs S, Godfrey K, Herod J, Leeson S, Mould T, Murdoch J, Oram D, Scott I, Seif MW, Williamson K, Woolas R, Fallowfield L, Campbell S, Skates SJ, Parmar M, Jacobs IJ. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British journal of cancer. 2017 Aug 22;117(5):619-627. Epub 2017 Jul 25. PMID: 28742794
  • Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer cell. 2013 Dec 9;24(6):751-65. PMID: 24332043
  • Skates SJ. EPIC Early Detection of Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Sep 15;22(18):4542-4. Epub 2016 Jul 14. PMID: 27418634
  • Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI insight. 2016 Aug 18;1. (13). PMID: 27617304
  • Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecologic oncology. 2011 Oct;123(1):5-12. Epub 2011 Jun 17. PMID: 21683992
  • Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Scientific reports. 2023 Jan 27;13(1):1537. PMID: 36707610
  • Kroeger PT Jr, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current opinion in obstetrics & gynecology. 2017 Feb;29(1):26-34. PMID: 27898521
  • Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015 Oct. PMID: 26629528
  • Kuhn E, Carr SA. Multiplexed Immunoaffinity Enrichment of Peptides with Anti-peptide Antibodies and Quantification by Stable Isotope Dilution Multiple Reaction Monitoring Mass Spectrometry. Methods in molecular biology (Clifton, N.J.). 2016;1410:135-67. PMID: 26867743
  • Gentry-Maharaj A, Blyuss O, Ryan A, Burnell M, Karpinskyj C, Gunu R, Kalsi JK, Dawnay A, Marino IP, Manchanda R, Lu K, Yang WL, Timms JF, Parmar M, Skates SJ, Bast RC Jr, Jacobs IJ, Zaikin A, Menon U. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers. 2020 Jul 17;12. (7). PMID: 32708856
  • Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC Jr. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American journal of obstetrics and gynecology. 2012 Apr;206(4):351.e1-8. Epub 2011 Dec 30. PMID: 22284961
  • Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer research. 2014 Feb 15;74(4):1141-52. Epub 2013 Dec 23. PMID: 24366882
  • Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nature reviews. Cancer. 2011 Sep 23;11(10):719-25. PMID: 21941283
  • Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Science translational medicine. 2012 Aug 15;4(147):147ra112. PMID: 22896676
  • Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26;160(5):977-989. PMID: 25723171
  • Perets R, Drapkin R. It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. Cancer research. 2016 Jan 1;76(1):10-7. Epub 2015 Dec 15. PMID: 26669862
  • O'Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee HJ, Kim WH, Yang HK, Shi C, Maitra A, Montgomery E, Washington MK, El Rifai W, Drapkin RI, Goldenring JR. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Human pathology. 2013 May;44(5):734-42. Epub 2012 Oct 16. PMID: 23084584
  • Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 May;22 Suppl 1(Suppl 1):S24-6. PMID: 22543916
  • Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jan 1;31(1):49-57. Epub 2012 Dec 3. PMID: 23213100
  • Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. Journal of visualized experiments : JoVE. 2011 May 9;(51). PMID: 21610668
  • Young Han C, Bedia JS, Yang WL, Hawley SJ, Bergan L, Hopper M, Celestino J, Guo J, Gornet TG, Soosaipillai A, Yang H, Doskocil SD, Lokshin AE, Handy BC, Diamandis EP, Moore RG, Lu KH, Lu Z, Anderson KS, Drescher CW, Skates SJ, Bast RC Jr. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. British journal of cancer. 2024 Mar;130(5):861-868. Epub 2024 Jan 9. PMID: 38195887
  • Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Mar 1;23(5):1263-1273. Epub 2016 Aug 29. PMID: 27573169
  • Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America. 2014 Jan 21;111(3):1102-7. Epub 2014 Jan 2. PMID: 24385586
  • Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. Journal of the National Cancer Institute. 2015 Feb 16;107. (4). Print 2015 Apr. PMID: 25688116
  • Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, Karlan BY, Oren M, Hoon DS, Drapkin R. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Cancer research. 2019 Feb 15;79(4):760-772. Epub 2018 Dec 18. PMID: 30563893
  • Anderson L, Razavi M, Skates S, Anderson NG, Pearson TW. Squeezing more value from the analytes we have: personal baselines for multiple analytes in serial DBS. Bioanalysis. 2016 Aug;8(15):1539-1542. Epub 2016 Jun 9. PMID: 27277878
  • Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 2015 Jan 15;34(3):373-83. Epub 2014 Jan 27. PMID: 24469047
  • Jones PM, Drapkin R. Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. Frontiers in oncology. 2013 Aug 26;3:217. doi: 10.3389/fonc.2013.00217. eCollection 2013. PMID: 23986883
  • Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 1;119(19):3454-61. Epub 2013 Aug 26. PMID: 23983047
  • Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2020 Dec;29(12):2504-2512. Epub 2020 Oct 13. PMID: 33051337
  • Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, Evans DG, Eccles DM, Ryan A, Liston R, Dawnay A, Ford J, Gunu R, Mackay J, Skates SJ, Menon U, Jacobs IJ, United Kingdom Familial Ovarian Cancer Screening Study collaborators. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 1;35(13):1411-1420. Epub 2017 Feb 27. PMID: 28240969
  • Sung CK, Li D, Andrews E, Drapkin R, Benjamin T. Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Molecular oncology. 2013 Jun;7(3):419-27. Epub 2012 Dec 12. PMID: 23273547
  • Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala EO, Whetton AD, Menon U, Jacobs I, Graham RL. Protein Z: A putative novel biomarker for early detection of ovarian cancer. International journal of cancer. 2016 Jun 15;138(12):2984-92. Epub 2016 Feb 19. PMID: 26815306
  • Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nature communications. 2017 Oct 23;8(1):1093. PMID: 29061967
  • Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget. 2017 Mar 3;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 1. PMID: 28881617
  • Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, Anderson C, Edlund CK, Conti D, Harrington P, Barrowdale D, Bowtell DD, Alsop K, Mitchell G, AOCS Study Group, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Bogdanova N, Dürst M, Hillemanns P, Ovarian Cancer Association Consortium, Odunsi K, Whittemore AS, Karlan BY, Dörk T, Goode EL, Menon U, Jacobs IJ, Antoniou AC, Pharoah PD, Gayther SA. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute. 2015 Aug 27;107. (11). Print 2015 Nov. PMID: 26315354
  • Novak M, Lester J, Karst AM, Parkash V, Hirsch MS, Crum CP, Karlan BY, Drapkin R. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Gynecologic oncology. 2015 Oct;139(1):104-11. Epub 2015 Jul 20. PMID: 26206555
  • Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 medicine reports. 2011;3:22. Epub 2011 Nov 1. PMID: 22076125
  • Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC Jr. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer prevention research (Philadelphia, Pa.). 2019 Jun;12(6):391-400. Epub 2019 Apr 9. PMID: 30967390
  • Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K, Australian Ovarian Cancer Study Group, Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M, Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ. PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. Journal of the National Cancer Institute. 2016 Jan 27;108. (3). Print 2016 Mar. PMID: 26823519
  • Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jun 20;33(18):2062-71. Epub 2015 May 11. PMID: 25964255
  • Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin RI. FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene. 2014 Aug 28;33(35):4424-32. Epub 2013 Sep 30. PMID: 24077281
  • Jacobs IJ, Parmar M, Skates SJ, Menon U. Ovarian cancer screening: UKCTOCS trial - Authors' reply. Lancet (London, England). 2016 Jun 25;387(10038):2603-2604. PMID: 27353822
  • Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. Gynecologic oncology. 2015 Oct;139(1):97-103. Epub 2015 Aug 29. PMID: 26321251
  • Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstetrics and gynecology. 2011 Aug;118(2 Pt 1):280-288. PMID: 21775843
  • Keshishian H, Burgess MW, Specht H, Wallace L, Clauser KR, Gillette MA, Carr SA. Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry. Nature protocols. 2017 Aug;12(8):1683-1701. Epub 2017 Jul 27. PMID: 28749931
  • Khleif SN, Doroshow JH, Hait WN, AACR-FDA-NCI Cancer Biomarkers Collaborative, Hait WN, Khleif SN, Doroshow JH, Gutman SI, Barker PE, Dracopoli NC, Gutierrez A, Skates SJ, Austin MJ, Bast RC Jr, Becker RL, Berry DA, Bradley LA, Bross PF, Chang M, Clark AM, Devanarayan V, Dressler LG, Endres DB, Enns RK, Frullo FJ, Harper CC, Hayes DF, Hinestrosa MC, Hinman L, Hruszkewycz A, Huang PS, Jessup JM, Juweid ME, Kalush F, Kaul KL, Kelloff G, Klee GG, Koch WH, Lemery S, Levy JB, Mansfield E, Maurey KM, Moseley GB 3rd, Naples R, Omel JP, Orr MS, Pennello GA, Pignato WJ, Ransohoff DF, Reid LH, Rodriguez H, Schilsky RL, Schueren R, Simon RM, Sluss PM, Sninsky JJ, Srivastava S, Taube SE, Taylor JM, van't Veer LJ, Vishnuvajjala L, Wang SJ, Warrington JA, Watson MS, Weiner RS, Yost J, Rajagopal G, Buetow KH, Tong W, Tucker-Kellogg G, Beck JR, Bryant BM, Crichton D, Kim P, McIntosh MW, O'Leary T, Orr MS, Saltz JH, Shih WJ, Siemers N, Speakman J, Spears P, Srivastava S, Stancampiano BA, Zhang Z, Zujewski J, Compton C, Holloway B, Jewell SD, Mansfield E, Blanchard KL, Cosentino LM, David KA, de Mars M, Dressler LG, Fore IM, Goldman P, Hammond EH, Hegele RG, Juhl HH, Lubensky IA, Miller GA, Mullaney BP, Philip R, Qualman SJ, Rohlfs EM, Sobel ME, Stern HM, Thompson EA, Demetri GD, Dhingra K, Kelloff GJ, Pazdur R, Adelman MJ, Alexander J, Barrett JC, Chang DD, Engel JM, Geoghegan C, Grayzel DS, Grochow LB, Johnston J, Kenkare-Mitra S, Pensak D, Spinella DG, Woollett GR. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Jul 1;16(13):3299-318. Epub 2010 May 25. PMID: 20501613
  • Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science translational medicine. 2016 Mar 9;8(329):329ra34. PMID: 26962158
  • Keshishian H, Burgess MW, Gillette MA, Mertins P, Clauser KR, Mani DR, Kuhn EW, Farrell LA, Gerszten RE, Carr SA. Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury. Molecular & cellular proteomics : MCP. 2015 Sep;14(9):2375-93. Epub 2015 Feb 27. PMID: 25724909
  • Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (London, England). 2016 Mar 5;387(10022):945-956. Epub 2015 Dec 17. PMID: 26707054
  • Gentry-Maharaj A, Glazer C, Burnell M, Ryan A, Berry H, Kalsi J, Woolas R, Skates SJ, Campbell S, Parmar M, Jacobs I, Menon U. Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ open. 2017 Mar 6;7(3):e011822. PMID: 28264823
  • Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer prevention research (Philadelphia, Pa.). 2011 Sep;4(9):1401-8. PMID: 21893500
  • Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC Jr, AOCS Study Group. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Oct 1;23(19):5912-5922. Epub 2017 Jun 21. PMID: 28637689
  • Holman LL, Lu KH, Bast RC Jr, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. American journal of obstetrics and gynecology. 2014 Mar;210(3):257.e1-6. Epub 2013 Nov 16. PMID: 24246524
  • Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. The Journal of clinical investigation. 2013 Oct;123(10):4435-48. Epub 2013 Sep 9. PMID: 24018557
  • Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Jul 15;23(14):3628-3637. Epub 2017 Jan 31. PMID: 28143870

Clinical Trials

Study Name Clinical Trial ID
Developing a Test for the Detection of Ovarian Cancer NCT04794322